CognitMarket market news, portfolio research, and investor insights

LONDON - Silence Therapeutics plc (NASDAQ:SLN) announced today that it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash transaction valued at approximately $1.3 billion in equity value and $1.1 billion in enterprise value, according to a press release statement.

Under the terms of the agreement, Silence shareholders will receive $20.00 in cash per American Depositary Share, with each ADS representing three ordinary shares. The offer represents a 130% premium to Silence’s closing ADS price on Friday and an 82% premium to the 30-day volume-weighted average price of $10.99.

The transaction will be effected through a U.K. scheme of arrangement under Part 26 of the UK Companies Act 2006. The deal is expected to close in the first quarter of 2027, subject to Silence shareholder approval, sanction by the High Court of Justice of England and Wales, and other customary closing conditions including regulatory approvals.

Investors tracking

In this article

Indonesia’s benchmark stock index plunged over 5% on Monday to its lowest level in six years, as concerns over a potential downgrade by MSCI intensified fears of further foreign investor outflows.

The Jakarta Composite Index tumbled to its lowest level since early October 2020, extending a bruising sell-off in Indonesian equities. MSCI, the index provider, on Friday proposed reclassifying Indonesia directly from an emerging market to stand-alone status, raising the prospect of the country’s removal from major global equity benchmarks.

MSCI is expected to make a final decision by June, with the potential reclassification hinging on whether Indonesian authorities can demonstrate meaningful improvements in market governance and transparency.

Goldman Sachs warned in a Sunday note that a full removal from MSCI’s emerging-market indexes could trigger approximately $5.6 billion in passive fund outflows, equivalent to 18 days of average daily trading volume for constituents

Investing.com -- Liveramp Holdings Inc (NYSE: RAMP) shares rose 2% Monday after the Federal Trade Commission approved Publicis Groupe SA's (EPA: PUBP) $2.2 billion acquisition of the company with conditions designed to preserve competition in the digital advertising market.

The FTC issued a consent order requiring Publicis to maintain neutral and nondiscriminatory access to LiveRamp's products and services and establish firewalls to prevent Publicis from accessing LiveRamp's customer data. The regulatory approval removes a key hurdle for the deal, which was announced in May at $38.50 per share.

The FTC's complaint raised concerns that Publicis's acquisition of LiveRamp, which provides data connectivity services for digital advertising, would harm competition in markets for media agency services and audience data services. The agency alleged that the deal would give Publicis the ability to foreclose customers of competing media agencies by leveraging control of LiveRamp to pressure cl

Investing.com - Jefferies downgraded EyePoint Inc. (NASDAQ:EYPT) to Hold from Buy and cut its price target to $1.00 from $8.00 on Monday. The stock plummeted to $0.45, down 86% from its previous close of $3.14, with shares now trading near their 52-week low and down 84% year-to-date.

The downgrade follows the company’s Phase 3 LUCIA study of Duravyu in wet age-related macular degeneration missing its primary endpoint of best corrected visual acuity non-inferiority to aflibercept. This marks the second Phase 3 trial setback after the LUGANO study also missed its endpoint.

EyePoint stated no study irregularities impacted the results and there are no meaningful subgroup differences. The company plans to analyze the results further, but Jefferies said a path forward in wet age-related macular degeneration appears unlikely.

The company’s Phase 3 diabetic macular edema program is fully enrolled with data expected in the fourth quarter of 2027. EyePoint reported cash of $118 million, or $1

Get personalized, AI-powered answers built on 27+ years of trusted expertise.

A rosy outlook has investors piling into shares of steel producer Cleveland-Cliffs.

Shares of Cleveland-Cliffs (CLF) were up over 14% in premarket trading, after the steelmaker’s adjusted EBITDA projections easily topped analysts’ expectations.

The company said it sees adjusted EBITDA of about $715 million for the fourth quarter of 2026, above the $683.6 million analysts surveyed by Visible Alpha called for. Cleveland-Cliffs projected 2027 adjusted EBITDA exceeding $4 billion, easily outdistancing the $2.54 billion consensus estimate.1

“We expect fourth quarter adjusted EBITDA to further increase, even with typical fourth-quarter seasonality and planned maintenance outages,” Cleveland-Cliffs CEO Lourenco Goncalves said. “We continued to reduce debt in Q3 and, with amplified free cash flow in Q4 and property sale proceeds, we expect a major debt reduction in the fourth quarter.”

In the third quarter, the

AUSTIN, Texas - XBiotech Inc. (NASDAQ:XBIT) announced today that its Phase II TASKIN clinical trial met its primary efficacy endpoint, with 61.3% of patients in the experimental arm surviving at 12 months.

The investigator-sponsored study, funded by the French National Cancer Institute and coordinated by Centre Georges-François Leclerc in Dijon, France, evaluated XBiotech’s anti-IL-1α monoclonal antibody XB2001 (vilamakitug) combined with standard chemotherapy in patients with refractory metastatic colorectal cancer.

The trial enrolled 159 evaluable patients randomized to receive either vilamakitug or placebo plus standard-of-care trifluridine/tipiracil with or without bevacizumab. At 12 months, 49 of 80 patients (61.3%) in the vilamakitug arm were alive, surpassing the protocol-defined threshold of 42 patients required to establish efficacy. The control arm showed 44 of 79 patients (55.7%) alive at 12 months.

Median progression-free survival was 5.9 months for the vilamakitug arm v